Reuters: Global Markets: Geron cancer drug highly effective in trial, shares soar

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Geron cancer drug highly effective in trial, shares soar Nov 7th 2013, 14:57 Thu Nov 7, 2013 9:57am EST (Reuters) - Geron Corp said 22 percent of patients treated by its experimental blood cancer drug in a clinical trial were free of the disease, and its shares more than doubled in value in early trading. The company also said that one patient, of the first 18 patients enrolled in the trial, showed a partial remission to the drug, known as imetelstat. Geron released the data ahead of a presentation on December 9 at the annual meeting of the American Society of Hematology. (link.reuters.com/suk54v) Shares of the company were up 97 percent at $7.10. They hit a four-year high of $7.79.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions